Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

Core Insights - Adverum Biotechnologies is a clinical-stage company focused on gene therapy for ocular diseases, aiming to establish a new standard of care [3] - The company will present at the Cowen 45th Annual Healthcare Life Sciences Conference on March 4, 2025 [1] - Adverum is developing a one-time intravitreal injection therapy, ixoberogene soroparvovec (Ixo-vec), for neovascular or wet age-related macular degeneration [3] Company Overview - Adverum Biotechnologies aims to develop functional cures to restore vision and prevent blindness through gene therapy [3] - The company utilizes a proprietary intravitreal (IVT) platform to create durable, single-administration therapies, reducing the need for frequent ocular injections [3] - Adverum's mission includes transforming the standard of care for debilitating ocular diseases and making a significant societal impact globally [3]